Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort II)
NCT ID: NCT04090957
Last Updated: 2025-12-26
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1015 participants
INTERVENTIONAL
2019-09-27
2022-08-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Arm 1, 2, and 3: randomized, double blind
\- Efficacy Study Part: designed to evaluate the frequency and severity of vasomotor symptoms \[VMS\] in both hysterectomized and non hysterectomized postmenopausal participants after treatment with two doses of E4 (15 mg or 20 mg) or placebo for 12 consecutive weeks. Thereafter, treatment proceeded for a total duration of up to 53 weeks, to continue the evaluation of secondary efficacy (effect on hemostasis, lipid and glucose metabolism, bone turnover, health-related quality of life \[HRQoL\] and treatment satisfaction \[TS\]), safety and the effect on the endometrium. For endometrial protection, all non-hysterectomized subjects received 200 mg progesterone (P4) once daily for 14 consecutive days, after completion of the E4/placebo treatment.
Arm 4: open label
\- Safety Study Part: designed to evaluate the general safety, secondary efficacy (lipid and glucose metabolism, HRQoL and TS) after treatment with E4 20 mg for up to 53 weeks in hysterectomized and non hysterectomized postmenopausal participants. For endometrial protection, all non-hysterectomized subjects received 200 mg progesterone (P4) once daily for 14 consecutive days, after completion of the E4 treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Estetrol 15 mg - Efficacy Study Part
Estetrol (E4) 15 mg, administered orally once daily for up to 53 weeks.
Estetrol oral tablet
Estetrol oral tablet, administered orally once daily.
Estetrol 20 mg - Efficacy Study Part
Estetrol (E4) 20 mg, administered orally once daily for up to 53 weeks.
Estetrol oral tablet
Estetrol oral tablet, administered orally once daily.
Placebo - Efficacy Study Part
Placebo, administered orally once daily for up to 53 weeks.
Placebo oral tablet
Placebo oral tablet, administered orally once daily.
Estetrol 20 mg - Safety Study Part
Estetrol (E4) 20 mg, administered orally once daily for up to 53 weeks.
Estetrol oral tablet
Estetrol oral tablet, administered orally once daily.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Estetrol oral tablet
Estetrol oral tablet, administered orally once daily.
Placebo oral tablet
Placebo oral tablet, administered orally once daily.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Females ≥ 40 up to ≤ 65 years of age at randomization/treatment allocation;
3. For hysterectomized subjects: documented hysterectomy must have occurred at least 6 weeks prior to the start of screening. Hysterectomy can be total or subtotal (i.e., cervix was not removed).
4. For non-hysterectomized subjects: uterus with bi-layer endometrial thickness ≤ 4 mm on transvaginal ultrasound (TVUS)
5. For non-hysterectomized subjects: endometrial biopsy taken during screening that reveals no abnormal result, i.e., presence of hyperplasia (simple or complex, with or without atypia), presence of carcinoma, and presence of disordered proliferative endometrium findings. The screening biopsy should have sufficient endometrial tissue for diagnosis. Biopsies without tissue or with insufficient tissue may be repeated once;
6. Seeking treatment for relief of VMS associated with menopause;
1. For the Efficacy Study part: at least 7 moderate to severe bothersome VMS per day or at least 50 moderate to severe bothersome VMS per week in the last 7 consecutive days during the Screening period;
2. For the Safety Study part: at least 1 moderate to severe VMS per week;
7. Body mass index ≥ 18.0 kg/m² up to ≤ 38.0 kg/m²;
8. A mammogram that shows no sign of significant disease performed during screening or within 9 months prior to the start of screening;
9. Post-menopausal status defined as any of the following:
1. For non-hysterectomized subjects:
Exclusion Criteria
2. For hysterectomized subjects:
* or at least 6 weeks post-surgical bilateral oophorectomy;
10. Good physical and mental health, in the judgement of the Investigator as based on medical history, physical and gynecological examination, and clinical assessments performed prior to Visit 1;
11. Able to understand and comply with the protocol requirements, instructions, and protocol-stated restrictions;
12. Able and willing to complete trial daily diaries and questionnaires.
1. History of malignancy, with the exception of basal cell or squamous cell carcinoma of the skin if diagnosed more than 1 year prior to the Screening visit;
2. Any clinically significant findings found by the Investigator at the breast examination and/or on mammography suspicious of breast malignancy that would require additional clinical testing to rule out breast cancer (however, simple cysts confirmed by ultrasound are allowed);
3. Papanicolaou (PAP) test with atypical squamous cells undetermined significance (ASC-US) or higher (low-grade squamous intraepithelial lesion \[LSIL\], atypical squamous cells- cannot exclude high-grade squamous intraepithelial lesion \[HSIL\] \[ASC-H\], HSIL dysplastic or malignant cells) in sub-totally hysterectomized and non-hysterectomized subjects. Note: ASC-US is allowed if a reflex human papilloma virus (HPV) testing is performed and is negative for high risk oncogene HPV subtypes 16 and 18;
4. For non-hysterectomized subjects:
1. History or presence of uterine cancer, endometrial hyperplasia, or disordered proliferative endometrium;
2. Presence of endometrial polyp;
3. Undiagnosed vaginal bleeding or undiagnosed abnormal uterine bleeding;
4. Endometrial ablation;
5. Any uterine/endometrial abnormality that in the judgment of the investigator contraindicates the use of estrogen and/or progestin therapy. This includes presence or history of adenomyosis or significant myoma;
5. Systolic blood pressure (BP) higher than 130 mmHg, diastolic BP higher than 80 mmHg during screening;
6. History of venous or arterial thromboembolic disease (e.g., superficial or deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction, angina pectoris, etc.), or first-degree family history of venous thromboembolism (VTE);
7. History of known acquired of congenital coagulopathy or abnormal coagulation factors, including known thrombophilia's;
8. Laboratory values of fasting glucose above 125 mg/dL and/or glycated hemoglobin above 7%;
9. Dyslipoproteinaemia (LDL \>190 mg/dL and/or triglycerides \>300 mg/dL);
10. Subjects smoking \>15 cigarettes per day;
11. Presence or history of gallbladder disease, unless cholecystectomy has been performed;
12. Systemic lupus erythematosus;
13. Any malabsorption disorders including gastric bypass surgery;
14. History of acute liver disease in the preceding 12 months before the start of screening or presence or history of chronic or severe liver disease \[alanine transaminase (ALT) or aspartate transaminase (AST) \>2 x upper limit of normal (ULN), bilirubin \>1.5 ULN\], or liver tumors;
15. Chronic or current acute renal impairment (estimated glomerular filtration rate \<60 ml/min);
16. Porphyria;
17. Diagnosis or treatment of major psychiatric disorder (e.g., schizophrenia, bipolar disorder, etc.) in the judgement of the Investigator;
18. Use of estrogen/progestin containing drug(s) up to:
1. 1 week before screening start for vaginal non-systemic hormonal products (rings, creams, gels);
2. 4 weeks before screening start for vaginal or transdermal estrogen or estrogen/progestin products;
3. 8 weeks before screening start for oral estrogen and/or progestin products and/or selective estrogen receptor modulator therapy;
4. 8 weeks before screening start for intrauterine progestin therapy;
5. 3 months before screening start for progestin implants or estrogen alone injectable drug therapy;
6. 6 months before screening start for estrogen pellet therapy or progestin injectable drug therapy;
19. Use of androgen/dehydroepiandrosterone (DHEA) containing drugs:
1. 8 weeks before screening start for oral, topical, vaginal or transdermal androgen;
2. 6 months before screening start for implantable or injectable androgen therapy;
20. Use of phytoestrogens or black cohosh for treatment of VMS up to 2 weeks before the start of screening;
21. For the women participating in the Efficacy Study part: use of prescription or over-the-counter products used for the treatment of VMS, e.g., anti-depressants: paroxetine, escitalopram, methyldopa, opioid and clonidine up to 4 weeks before the start of screening, and venlafaxine and desvenlafaxine up to 3 months before the start of screening , and not willing to stop these during their participation in the trial;
23. Inadequately treated hyperthyroidism with abnormal thyroid stimulating hormone (TSH) and free T4 at screening. Subjects with low or high TSH are allowed if free T4 at screening is within normal range;
24. History or presence of allergy/intolerance to the investigational product or drugs of this class or any component of it, or history of drug or other allergy that, in the opinion of the Investigator contraindicates subject participation;
25. For non-hysterectomized subjects: history or presence of allergy to peanuts;
26. History of alcohol or substance abuse (including marijuana, even if legally allowed) or dependence in the previous 12 months before the start of screening as determined by the Investigator, based on reported observations;
27. Sponsor or contract research organization (CRO) employees or employees under the direct supervision of the Investigator and/or involved directly in the trial;
28. Subjects with known or suspected history of a clinically significant systemic disease, unstable medical disorders, life-threatening disease or current malignancies that would pose a risk to the subject in the opinion of the Investigator;
29. Participation in another investigational drug clinical trial within 1 month (30 days) or having received an investigational drug within the last month (30 days) before the start of screening;
30. Is judged by the Investigator to be unsuitable for any reason.
40 Years
65 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ICON Clinical Research
INDUSTRY
Estetra
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Estetra
Role: STUDY_DIRECTOR
Estetra
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Estetra Study Site
Birmingham, Alabama, United States
Estetra Study Site
Birmingham, Alabama, United States
Estetra Study Site
Birmingham, Alabama, United States
Estetra Study Site
Dothan, Alabama, United States
Estetra Study Site
Phoenix, Arizona, United States
Estetra Study Site
Phoenix, Arizona, United States
Estetra Study Site
Tempe, Arizona, United States
Estetra Study Site
Tucson, Arizona, United States
Estetra Study Site
Tucson, Arizona, United States
Estetra Study Site
Tucson, Arizona, United States
Estetra Study Site
Tucson, Arizona, United States
Estetra Study Site
Little Rock, Arkansas, United States
Estetra Study Site
Bellflower, California, United States
Estetra Study Site
Canoga Park, California, United States
Estetra Study Site
Chula Vista, California, United States
Estetra Study Site
Huntington Beach, California, United States
Estetra Study Site
La Mesa, California, United States
Estetra Study Site
Lincoln, California, United States
Estetra Study Site
Los Angeles, California, United States
Estetra Study Site
Pomona, California, United States
Estetra Study Site
Sacramento, California, United States
Estetra Study Site
San Diego, California, United States
Estetra Study Site
San Diego, California, United States
Estetra Study Site
Santa Ana, California, United States
Estetra Study Site
Thousand Oaks, California, United States
Estetra Study Site
West Covina, California, United States
Estetra Study Site
Colorado Springs, Colorado, United States
Estetra Study Site
Denver, Colorado, United States
Estetra Study Site
Crystal River, Florida, United States
Estetra Study Site
Jacksonville, Florida, United States
Estetra Study Site
Jacksonville, Florida, United States
Estetra Study Site
Miami, Florida, United States
Estetra Study Site
Miami, Florida, United States
Estetra Study Site
Miami, Florida, United States
Estetra Study Site
Miami Lakes, Florida, United States
Estetra Study Site
New Port Richey, Florida, United States
Estetra Study Site
Ocoee, Florida, United States
Estetra Study Site
Orlando, Florida, United States
Estetra Study Site
Sarasota, Florida, United States
Estetra Study Site
West Palm Beach, Florida, United States
Estetra Study Site
Atlanta, Georgia, United States
Estetra Study Site
Morrow, Georgia, United States
Estetra Study Site
Sandy Springs, Georgia, United States
Estetra Study Site
Savannah, Georgia, United States
Estetra Study Site
Idaho Falls, Idaho, United States
Estetra Study Site
Meridian, Idaho, United States
Estetra Study Site
Evansville, Indiana, United States
Estetra Study Site
Marrero, Louisiana, United States
Estetra Study Site
Saginaw, Michigan, United States
Estetra Study Site
Saginaw, Michigan, United States
Estetra Study Site
Rochester, Minnesota, United States
Estetra Study Site
St Louis, Missouri, United States
Estetra Study Site
Lincoln, Nebraska, United States
Estetra Study Site
Norfolk, Nebraska, United States
Estetra Study Site
Las Vegas, Nevada, United States
Estetra Study Site
Las Vegas, Nevada, United States
Estetra Study Site
Albuquerque, New Mexico, United States
Estetra Study Site
Albuquerque, New Mexico, United States
Estetra Study Site
New York, New York, United States
Estetra Study Site
Charlotte, North Carolina, United States
Estetra Study Site
Charlotte, North Carolina, United States
Estetra Study Site
Columbus, North Carolina, United States
Estetra Study Site
Fayetteville, North Carolina, United States
Estetra Study Site
Hickory, North Carolina, United States
Estetra Study Site
New Bern, North Carolina, United States
Estetra Study Site
Raleigh, North Carolina, United States
Estetra Study Site
Raleigh, North Carolina, United States
Estetra Study Site
Rocky Mount, North Carolina, United States
Estetra Study Site
Cincinnati, Ohio, United States
Estetra Study Site
Cincinnati, Ohio, United States
Estetra Study Site
Cleveland, Ohio, United States
Estetra Study Site
Columbus, Ohio, United States
Estetra Study Site
Columbus, Ohio, United States
Estetra Study Site
Fairfield, Ohio, United States
Estetra Study Site
Erie, Pennsylvania, United States
Estetra Study Site
Philadelphia, Pennsylvania, United States
Estetra Study Site
Bluffton, South Carolina, United States
Estetra Study Site
Columbia, South Carolina, United States
Estetra Study Site
Mt. Pleasant, South Carolina, United States
Estetra Study Site
Myrtle Beach, South Carolina, United States
Estetra Study Site
North Charleston, South Carolina, United States
Estetra Study Site
Chattanooga, Tennessee, United States
Estetra Study Site
Jefferson City, Tennessee, United States
Estetra Study Site
Knoxville, Tennessee, United States
Estetra Study Site
Knoxville, Tennessee, United States
Estetra Study Site
Memphis, Tennessee, United States
Estetra Study Site
Memphis, Tennessee, United States
Estetra Study Site
Dallas, Texas, United States
Estetra Study Site
Fort Worth, Texas, United States
Estetra Study Site
Fort Worth, Texas, United States
Estetra Study Site
Georgetown, Texas, United States
Estetra Study Site
Houston, Texas, United States
Estetra Study Site
Houston, Texas, United States
Estetra Study Site
Houston, Texas, United States
Estetra Study Site
Houston, Texas, United States
Estetra Study Site
Houston, Texas, United States
Estetra Study Site
Houston, Texas, United States
Estetra Study Site
McAllen, Texas, United States
Estetra Study Site
McAllen, Texas, United States
Estetra Study Site
Pearland, Texas, United States
Estetra Study Site
Plano, Texas, United States
Estetra Study Site
San Antonio, Texas, United States
Estetra Study Site
Draper, Utah, United States
Estetra Study Site
Pleasant Grove, Utah, United States
Estetra Study Site
West Jordan, Utah, United States
Estetra Study Site
Charlottesville, Virginia, United States
Estetra Study Site
Norfolk, Virginia, United States
Estetra Study Site
Virginia Beach, Virginia, United States
Estetra Study Site
Bellevue, Washington, United States
Estetra Study Site
Seattle, Washington, United States
Estetra Study Site
Morgantown, West Virginia, United States
Estetra Study Site
Red Deer, Alberta, Canada
Estetra Study Site
Montreal, Quebec, Canada
Estetra Study Site
Brampton, , Canada
Estetra Study Site
Québec, , Canada
Estetra Study Site
Québec, , Canada
Estetra Study Site
Waterloo, , Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Panay N, Simoncini T, Taziaux M, Bouchard C, Black A, Kapoor E, Utian W, Foidart JM, Lobo RA. Estetrol for the treatment of moderate to severe vasomotor symptoms in postmenopausal women: The design of the E4COMFORT I and II trials. Maturitas. 2025 Nov 17;204:108781. doi: 10.1016/j.maturitas.2025.108781. Online ahead of print.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan: Efficacy Study Part (ESP)
Document Type: Statistical Analysis Plan: Safety Study Part (SSP)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MIT-Do001-C302
Identifier Type: -
Identifier Source: org_study_id